Alpha Teknova (TKNO) Stock Overview
Produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TKNO Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alpha Teknova, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.81 |
| 52 Week High | US$7.36 |
| 52 Week Low | US$1.91 |
| Beta | 0.47 |
| 1 Month Change | 35.11% |
| 3 Month Change | 82.30% |
| 1 Year Change | -46.03% |
| 3 Year Change | 93.40% |
| 5 Year Change | n/a |
| Change since IPO | -84.76% |
Recent News & Updates
Analyst Estimates: Here's What Brokers Think Of Alpha Teknova, Inc. (NASDAQ:TKNO) After Its First-Quarter Report
Alpha Teknova, Inc. ( NASDAQ:TKNO ) defied analyst predictions to release its quarterly results, which were ahead of...TKNO: Long Term Revenue Guidance Will Support Future Upside Potential
Analysts have adjusted their price target on Alpha Teknova to $7.00 per share from $7.00, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, with an expected total revenue range of $42 million to $44 million (company guidance).TKNO: Long Term Revenue Guidance And Higher P/E Will Support Future Upside
Analysts have adjusted their price target on Alpha Teknova to $7.00 from $7.00, reflecting updated views on discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, indicating an expected total revenue range of $42 million to $44 million.Recent updates
Shareholder Returns
| TKNO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 6.1% | -0.2% | 2.6% |
| 1Y | -46.0% | -1.1% | 26.2% |
Return vs Industry: TKNO underperformed the US Life Sciences industry which returned 7.9% over the past year.
Return vs Market: TKNO underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| TKNO volatility | |
|---|---|
| TKNO Average Weekly Movement | 12.7% |
| Life Sciences Industry Average Movement | 8.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TKNO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TKNO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 158 | Stephen Gunstream | www.teknova.com |
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company’ primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
Alpha Teknova, Inc. Fundamentals Summary
| TKNO fundamental statistics | |
|---|---|
| Market cap | US$205.34m |
| Earnings (TTM) | -US$17.17m |
| Revenue (TTM) | US$41.80m |
Is TKNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TKNO income statement (TTM) | |
|---|---|
| Revenue | US$41.80m |
| Cost of Revenue | US$27.58m |
| Gross Profit | US$14.22m |
| Other Expenses | US$31.39m |
| Earnings | -US$17.17m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 34.01% |
| Net Profit Margin | -41.07% |
| Debt/Equity Ratio | 20.3% |
How did TKNO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 08:18 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alpha Teknova, Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Paul Knight | KeyBanc Capital Markets Inc. |